Anticoagulant Availability in Hospital Pharmacies India
Why warfarin still outperforms DOACs for rheumatic heart disease in India, dabigatran's cost-effectiveness gap, and anticoagulant availability hospital pharmacy planning.
This piece covers what that evidence actually shows, why warfarin retains a genuine clinical and economic role in Indian anticoagulation practice that it has lost in many other markets, and what that means for how a hospital pharmacy stocks and monitors both drug classes.
Does a direct oral anticoagulant always outperform warfarin?
Not universally, and India's disease pattern is exactly where this matters. The INVICTUS trial, enrolling more than 4,500 patients with rheumatic heart disease-associated atrial fibrillation across Africa, Asia and South America, found that vitamin K antagonist therapy (warfarin) produced a lower rate of cardiovascular events or death than rivaroxaban, without a difference in major bleeding risk.
Rheumatic heart disease remains substantially more prevalent in India than in the high-income markets where most DOAC trial evidence was generated, which is precisely why this specific trial result matters more for Indian prescribing than it does for many Western guideline populations built on non-rheumatic atrial fibrillation data.
Is dabigatran cost-effective compared to warfarin in the Indian healthcare system?
A published cost-utility analysis found dabigatran improved life-years and quality-adjusted life-years over warfarin for stroke prevention in nonvalvular atrial fibrillation, but its incremental cost-effectiveness ratio came in well above India's standard cost-effectiveness threshold at both tested doses. The same analysis calculated that a substantial price reduction, roughly 49% on the 150 mg dose, would be needed to bring dabigatran within India's cost-effectiveness threshold.
This is a genuinely different picture from cost-effectiveness findings in high-income healthcare systems, where DOAC pricing sits closer to the relevant threshold already. For an Indian hospital, it means warfarin is not simply an older, inferior option being phased out; it remains the economically rational default for a large share of atrial fibrillation patients.
Why does warfarin still require more monitoring infrastructure than DOACs?
Warfarin's narrower therapeutic index and its need for regular INR testing to keep patients within target range is the core trade-off against the lower monitoring burden of DOACs. Anticoagulant availability hospital pharmacy planning has to budget for this monitoring infrastructure directly, not just the drug itself.
A hospital continuing to prescribe warfarin at meaningful volume, whether for cost reasons or for rheumatic heart disease patients specifically, needs a functioning, reliably accessible INR testing pathway as a structural requirement of that prescribing choice, not an optional add-on.
A hospital that prescribes warfarin without a dependable INR monitoring service is taking on real anticoagulation-control risk it may not be resourced to manage safely.
What does this mean for anticoagulant stocking priorities in a hospital pharmacy?
A pharmacy serving a general cardiology and internal medicine population in India needs warfarin stocked reliably and in volume, not treated as a legacy drug being wound down. Both the INVICTUS trial finding for rheumatic disease and the cost-effectiveness gap documented for dabigatran support this.
DOACs still have a clear and appropriate role for many non-rheumatic atrial fibrillation patients able to afford them. Stocking both categories deliberately, rather than defaulting entirely to one, matches the actual clinical and economic evidence rather than a global prescribing trend that doesn't map cleanly onto India's disease pattern.
Injectable anticoagulants, heparin and low-molecular-weight heparin formulations, remain a separate, high-turnover inpatient stocking need for acute indications and require their own reorder discipline distinct from the oral anticoagulant conversation entirely.
Why does reliable in-house anticoagulant stocking and monitoring matter for continuity of care?
An anticoagulated patient, whether on warfarin or a DOAC, depends on consistent access to both the exact prescribed drug and, for warfarin specifically, a dependable INR monitoring relationship with the prescribing institution. When a hospital's own pharmacy can't fill this prescription reliably, the patient sources it from an outside chemist disconnected from the hospital's own monitoring and interaction-screening record, a genuine safety gap given how narrow warfarin's therapeutic window is.
Our prescription leakage guide covers what this kind of walk-out costs a hospital across a chronic anticoagulation relationship, and our managed hospital pharmacy services piece covers how reliable in-house stocking keeps both warfarin and DOAC therapy, along with their respective monitoring needs, inside one hospital system.
Sources
- 1Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India — Value in Health Regional Issues, PubMed, National Library of Medicine
- 2Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation (INVICTUS trial) — New England Journal of Medicine, PubMed, National Library of Medicine
- 3Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
- 4National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation
- 5National Pharmaceutical Pricing Authority — drug price control and margin regulation
This article is for informational purposes and is not a substitute for professional medical advice. Anticoagulant choice and monitoring are clinical decisions for the treating doctor based on the individual patient. Consult a qualified physician before starting or stopping any treatment.
FAQ
Frequently asked questions
No. A large international trial found warfarin outperformed rivaroxaban specifically in rheumatic heart disease-associated atrial fibrillation, a condition much more common in India, and a separate Indian cost-utility analysis found dabigatran not currently cost-effective at standard pricing, meaning warfarin retains a genuine role in Indian practice.
A published cost-utility analysis found dabigatran's incremental cost-effectiveness ratio exceeded India's cost-effectiveness threshold at both tested doses, calculating that roughly a 49% price reduction on the 150 mg dose would be needed to bring it within that threshold.
Evidence from a large international trial specifically found vitamin K antagonist therapy (warfarin) more effective than rivaroxaban in rheumatic heart disease-associated atrial fibrillation, a distinction relevant to India given the condition's continued prevalence there.
Warfarin has a narrow therapeutic index and requires regular INR blood testing to keep patients in a safe and effective range, whereas DOACs generally do not require routine coagulation monitoring, which is their main practical advantage where cost allows their use.
Yes, generally. Given India's disease pattern and cost-effectiveness evidence, both categories serve genuinely different patient populations, and a hospital pharmacy defaulting entirely to one category risks under-serving patients for whom the other is the more appropriate or affordable choice.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.